Crohn’s disease is a chronic inflammatory bowel disease (IBD) that can affect any part of the digestive tract, from the mouth to the rectum. It’s characterized by inflammation that extends through all layers of the intestinal wall (transmural inflammation) and most commonly affects the last part of the small intestine (terminal ileum) and the colon. The disease is marked by alternating periods of flare-ups and remission, significantly affecting patients’ quality of life.
Crohn’s disease is relatively common, with higher incidence in developed countries and urban areas. It typically develops in young adulthood, between ages 15 and 30, though it can appear at any age. In recent years, incidence has been increasing globally, including in regions that traditionally had lower rates.
Symptoms vary depending on the location and severity of inflammation. Common symptoms include:
- Abdominal pain and cramping — often in the lower right abdomen when the terminal ileum is affected
- Chronic diarrhea — which can be watery or liquid, with or without blood. In severe cases, patients may have more than 20 bowel movements daily
- Weight loss and decreased appetite — due to inflammation, pain, and reduced food intake
- Fatigue and weakness — which may result from anemia, malnutrition, or the inflammation itself
- Fever — especially during flare-ups
- Intestinal bleeding — less frequent than in ulcerative colitis, but still present
- Mouth ulcers — fairly common in Crohn’s patients
- Perirectal symptoms — such as pain, itching, fissures, fistulas, or abscesses around the rectum
Additionally, many patients experience extraintestinal manifestations affecting other body organs, such as arthritis, eye inflammation (uveitis, iritis), skin manifestations (pyoderma gangrenosum, erythema nodosum), kidney stones, and osteoporosis.
Causes and Risk Factors
The exact cause of Crohn’s disease remains unknown, but research shows it’s a multifactorial disease resulting from the interaction of genetic, immunological, and environmental factors:
- Genetic predisposition — More than 200 genes have been associated with the disease, including the NOD2 (CARD15) gene, the first clearly recognized susceptibility gene. Family history is the strongest risk factor; 5-20% of patients have a first-degree relative with IBD, and if both parents have IBD, the risk for children reaches 36%
- Immune dysfunction — The disease results from an excessive and uncontrolled immune response to gut bacteria. Th1 and Th17 cells and cytokines such as TNF-α, IL-12, IL-18, and INF-γ play central roles in pathogenesis
- Intestinal microbiota — Disturbances in gut bacterial composition (dysbiosis) can trigger immune response
- Environmental factors:
- Smoking — The most important controllable risk factor. Smoking increases disease risk and is associated with more severe course, increased need for surgery, and higher relapse frequency
- Diet — Diets rich in processed foods, animal fats, and low in plant fiber may increase risk
- Antibiotics — Particularly use in early life has been associated with increased risk
- Urbanization and hygiene — The disease is more common in developed countries and urban areas, supporting the hygiene hypothesis
- Other factors — NSAIDs and contraceptives have been associated with increased risk or disease worsening
There’s no single diagnostic test for Crohn’s disease. Diagnosis is based on a combination of clinical, laboratory, endoscopic, imaging, and histological findings:
Laboratory Tests
- Complete blood count — May reveal anemia, leukocytosis, or thrombocytosis
- Inflammatory markers — Elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), though may be normal in mild disease
- Fecal calprotectin — High levels (>50-100 mg/g) indicate intestinal inflammation and help distinguish from functional disorders like IBS
- Infection screening — Stool cultures and testing for Clostridioides difficile
Endoscopic Examination
- Colonoscopy — Essential for direct visualization of the colon and terminal ileum, biopsy sampling, and disease severity assessment. Colonoscopy reveals characteristic findings such as segmental distribution of ulcers, lymphoid follicles (“cobblestone appearance”), aphthous ulcers, and strictures
- Biopsies — At least two biopsies from the terminal ileum and four from different colon sections are recommended. Histological examination may reveal non-caseating granulomas, characteristic (though not always present) of Crohn’s disease
- Upper endoscopy (gastroscopy) — May be needed in selected cases to evaluate the upper digestive tract
Imaging Studies
- MR Enterography (MRE) or CT Enterography (CTE) — Primary methods for evaluating the small intestine, identifying strictures, fistulas, and complications. MRE is preferred due to absence of radiation
- Intestinal Ultrasound (IUS) — Emerging as a non-invasive, radiation-free method for disease diagnosis and monitoring
Diagnosis requires exclusion of infectious causes (tuberculosis, Yersinia, Salmonella, Campylobacter) and other conditions mimicking Crohn’s disease (ulcerative colitis, Behçet’s disease, ischemic colitis).
Crohn’s Disease Phenotypes
According to the Montreal classification, disease is categorized as:
- Inflammatory phenotype (B1) — Characterized by inflammation without strictures or fistulas
- Stricturing phenotype (B2) — With strictures and intestinal obstruction
- Penetrating phenotype (B3) — With fistula, abscess, or perforation formation
- Perianal disease — Can coexist with any of the above phenotypes
Understanding the phenotype is critical for selecting appropriate treatment strategy.
Treatment and Management
Crohn’s disease treatment is individualized and aims to achieve clinical and endoscopic remission, prevent complications, and improve quality of life. Recent guidelines (2024-2025) support early initiation of advanced therapy in moderate to severe disease without requiring prior failure of conventional treatments.
Medication
- Corticosteroids — Used to induce remission during acute flare-ups. Budesonide (9 mg daily) is preferred for mild to moderate ileocecal disease due to fewer side effects. Not recommended for long-term maintenance therapy
- Mesalamine — No longer recommended for Crohn’s disease due to limited effectiveness
- Immunosuppressants:
- Thiopurines (azathioprine, 6-mercaptopurine) — Used for remission maintenance and reducing corticosteroid dependence
- Methotrexate — Effective for inducing and maintaining remission, especially in patients not responding to thiopurines
- Biologic Agents — Cornerstone of modern therapy for moderate to severe disease:
- TNF-α inhibitors (infliximab, adalimumab, certolizumab) — Highly effective for remission induction and maintenance, fistula treatment, and extraintestinal manifestations. Infliximab is the only agent with proven effectiveness for perianal disease
- Ustekinumab (Stelara) — Interleukin-12/23 inhibitor
- Risankizumab (Skyrizi) — Interleukin-23 inhibitor, recently approved for moderate to severe disease
- Vedolizumab (Entyvio) — Gut-selective integrin antagonist
- Small Molecules — Include JAK inhibitors (upadacitinib), offering new therapeutic options with subcutaneous or oral administration
Dietary Intervention
- Recent guidelines recognize potential of dietary therapy (Mediterranean diet, specific carbohydrate diet) for mild disease, with careful monitoring
- Nutritional support is critical for addressing malnutrition and micronutrient deficiencies
Surgery
Approximately 50% of patients will require surgery within 10 years of diagnosis. Indications include:
- Intestinal obstruction from strictures
- Fistulas, abscesses, or perforations
- Bleeding not controlled by conservative management
- Failure of medical therapy
Surgical options include intestinal resection, strictureplasty, and perianal procedures. Recurrence after surgery is common (~90% endoscopic recurrence in 5 years), so post-operative medical prophylaxis and monitoring are essential.
Crohn's Disease Complications
The disease can lead to serious complications:
- Intestinal obstruction — From strictures and scarring
- Fistulas — Abnormal passages between bowel segments or to other organs
- Abscesses — Require immediate intervention
- Malnutrition and deficiencies — Iron, vitamin B12, D, K, calcium, zinc, magnesium, and other micronutrients
- Increased colorectal cancer risk — Especially in patients with long-standing and extensive colon disease
Prognosis and Quality of Life
Crohn’s disease is chronic and incurable, but with proper management, many patients live productive lives with extended periods of remission. Studies show that life expectancy has improved in recent years thanks to new therapies. However, Crohn’s disease is associated with reduced life expectancy of 5-8 years compared to the general population, mainly due to complications. Quality of life is significantly affected, particularly by chronic pain, fatigue, and social restrictions.
When to See a Doctor
You should consult a doctor if:
- You experience persistent diarrhea for more than two weeks
- You notice blood in stool
- You experience unexplained weight loss
- You have fever lasting several days
- You experience severe abdominal pain that persists or worsens
- You have a family history of IBD or colorectal cancer
Early diagnosis and appropriate treatment can significantly improve quality of life and effectively manage Crohn’s disease symptoms.